Patricia Pacetti
Nurse Practitioner · Boston, MANPI 1982845590
Payments from drug & device makers
Across 43 payments — averaging $100.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$472
- Johnson & Johnson$454
- Amgen$444
- AstraZeneca$375
- Madrigal Pharmaceuticals$272
- Mylan Specialty L.p.$224
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,330100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 2 | $472 |
| Johnson & Johnson | 4 | $454 |
| Amgen | 4 | $444 |
| AstraZeneca(2 entities) | 3 | $375 |
| Madrigal Pharmaceuticals | 2 | $272 |
| Mylan Specialty L.p. | 2 | $224 |
| Esperion Therapeutics, Inc. | 2 | $219 |
| Cequr Corporation | 1 | $150 |
| Alnylam Pharmaceuticals Inc. | 1 | $146 |
| Abbott | 6 | $138 |
| Abiomed | 2 | $130 |
| Agios Pharmaceuticals, Inc. | 1 | $126 |
| Impulse Dynamics (USA) Inc. | 1 | $122 |
| Eisai Inc. | 1 | $122 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Neurocrine Biosciences, Inc. | 1 | $108 |
| AbbVie | 1 | $107 |
| Otsuka America Pharmaceutical, Inc. | 1 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $104 |
| Alkermes, Inc. | 1 | $99 |
| GSK | 1 | $89 |
| Inspire Medical Systems, Inc. | 1 | $76 |
| Agile Therapeutics, Inc. | 1 | $73 |
| Xeris Pharmaceuticals, Inc. | 1 | $44 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,330 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 45 | $65,334 |
| EliquisApixaban | 40 | $55,215 |
| Flecainide Acetate | 33 | $2,292 |
| Amiodarone Hcl | 20 | $1,074 |
| Metoprolol Succinate | 45 | $836 |
| Losartan Potassium | 41 | $341 |
| Atorvastatin Calcium | 21 | $306 |
| Atenolol | 12 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $454 | $65,33445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Boston
- Alison McManusBoston$346K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Miu Lai NgBoston$33K
- Lauren BurkeBoston$26K
- Ashley HilmesBoston$24K
- Kristina SkarbinskiBoston$24K
- Hilary UgrasBoston$19K
- Colleen TigheBoston$17K
- Stephanie McDonaldBoston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.